|
|
???tair.name??? >
???browser.page.title.author???
|
"li cp"???jsp.browse.items-by-author.description???
Showing items 1-50 of 75 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2024-03-25 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang, CY;Yang, SH;Li, CP;Su, YY;Chiu, SC;Bai, LY;Shan, YS;Chen, LT;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chiang, NJ;Chou, WC |
| 國家衛生研究院 |
2023-12-31 |
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
|
Su, YY;Chiang, NJ;Chiu, TJ;Huang, CJ;Hsu, SJ;Lin, HC;Yang, SH;Yang, Y;Chou, WC;Chen, YY;Bai, LY;Li, CP;Chen, JS |
| 國家衛生研究院 |
2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors
|
Lin, CC;Chiang, NJ;Lee, JH;Chen, MH;Chao, Y;Su, WC;Bai, LY;Wu, SY;Hsu, CH;Shan, YS;Li, CP;Chen, SH;Chung, WP;Chen, LT |
| 國家衛生研究院 |
2023-04-11 |
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized
|
Chiu, YF;Liu, TW;Shan, YS;Chen, JS;Li, CP;Ho, CL;Hsieh, RK;Hwang, TL;Chen, LT;Ch'ang, HJ; Taiwan Cooperative Oncology Group pancreatic cancer study group, |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chen, YY;Hsueh, SW;Yang, SH;Chiu, SC;Chiang, NJ;Chiu, TJ;Li, CP;Bai, LY;Chiu, CF;Chuang, SC;Shan, YS;Chan, DCA;Chen, LT;Yen, CJ;Peng, CM;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2021-12-17 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su, YY;Chiu, YF;Li, CP;Yang, SH;Lin, J;Lin, SJ;Chang, PY;Chiang, NJ;Shan, YS;Ch’ang, HJ;Chen, LT |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國家衛生研究院 |
2019-12-17 |
Endothelial-mesenchymal transition harnesses HSP90alpha-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
|
Fan, CS;Chen, LL;Hsu, TA;Chen, CC;Chua, KV;Li, CP;Huang, TS |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study
|
Chang, HJ;Chiu, YF;Chen, JS;Li, CP;Ho, CL;Shyr, YM;Chiou, WC;Yeh, CN;Hsieh, RK;Lin, YL;Tien, YW;Hwang, TL;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2018-04-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients
|
Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development
|
Chen, CC;Chen, LL;Li, CP;Hsu, YT;Jiang, SS;Fan, CS;Chua, KV;Huang, SX;Shyr, YM;Chen, LT;Huang, TS |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
|
Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
|
Wang-Gillam, A;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, FA;Mody, PD;Von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Siveke, JT;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, F;Mody, PD;Chen, LT;Von Hoff, DD |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial
|
Chen, MH;Lin, J;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國立交通大學 |
2014-12-08T15:46:20Z |
Temperature control with a neural fuzzy inference network
|
Lin, CT; Juang, CF; Li, CP |
| 國立交通大學 |
2014-12-08T15:45:22Z |
Water bath temperature control with a neural fuzzy inference network
|
Lin, CT; Juang, CF; Li, CP |
| 國立交通大學 |
2014-12-08T15:34:24Z |
Properties of covalently bonded layered-silicate/polystyrene nanocomposites synthesized via atom transfer radical polymerization
|
Li, CP; Huang, CM; Hsieh, MT; Wei, KH |
| 國立交通大學 |
2014-12-08T15:27:40Z |
Temperature control with a neural fuzzy inference network
|
Lin, CT; Juang, CF; Li, CP |
| 國立交通大學 |
2014-12-08T15:17:38Z |
Enhanced collective electron transport by CdSe quantum dots confined in the poly(4vinylpyridine) nanodomains of a poly(styrene-b-4-vinylpyridine) diblock copolymer thin film
|
Li, CP; Wei, KH; Huang, JY |
| 國立交通大學 |
2014-12-08T15:17:14Z |
Effect of the orientation of CdSe nanorods on the electron mobility of CdSe/P4VP nanodomains self-assembled within a poly(styrene-b-(4)-vinyipyridine) diblock copolymer thin film
|
Li, CP; Yeh, SW; Chang, HC; Huang, JY; Wei, KH |
| 國家衛生研究院 |
2014-07 |
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of High-Dose 5-Fluorouracil and Leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen, YC;Li, CP;Yen, CJ;Hsu, C;Lin, YL;Lin, ZZ;Chen, LT;Su, WC;Chao, Y;Yeh, KH;Cheng, AL |
| 國家衛生研究院 |
2014-05-06 |
Combination of a fast cleanup procedure and a DR-CALUX® bioassay for dioxin surveillance in Taiwanese soils
|
Lin, DY;Lee, YP;Li, CP;Chi, KH;Liang, BWP;Liu, WY;Wang, CC;Lin, S;Chen, TC;Yeh, KJC;Hsu, PC;Hsu, YC;Chao, HR;Tsou, TC |
| 高雄醫學大學 |
2014 |
雙週給予將capecitabine及oxaliplatin合併作為一線化療藥物治療局部晚期或轉移胃癌的多中心臨床試驗第二期
|
趙毅;謝建勳;葉顯堂;蘇裕傑;吳誠中;陳仁熙;戴承正;白禮源;葉坤輝;蘇五州;李重賓; Y1, Chao;Hsieh, JS;Yeh, HT;Su, YC;Wu, CC;Chen, JS;Tai, CJ;Bai, LY;Yeh, KH;Su, WC;Li, CP. |
Showing items 1-50 of 75 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
